Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PVLANASDAQ:TERNNASDAQ:TSVTNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePVLAPalvella Therapeutics$24.30-1.9%$23.74$6.20▼$29.27$273.97M0.167,824 shs83,965 shsTERNTerns Pharmaceuticals$3.12+0.6%$2.78$1.87▼$11.40$272.49M-0.161.53 million shs730,860 shsTSVT2seventy bio$5.00$4.98$2.29▼$5.30$266.15M1.04638,283 shsN/AUNCYUnicycive Therapeutics$0.59-0.3%$0.59$0.20▼$0.96$70.93M2.141.50 million shs759,158 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePVLAPalvella Therapeutics-1.94%+2.45%+0.08%+25.45%+2,429,999,900.00%TERNTerns Pharmaceuticals+0.65%+3.31%-5.45%-15.45%-53.78%TSVT2seventy bio0.00%0.00%+0.20%+89.39%+18.48%UNCYUnicycive Therapeutics+0.19%+6.29%-9.76%+6.85%-30.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPVLAPalvella Therapeutics3.9079 of 5 stars4.60.00.00.02.94.20.6TERNTerns Pharmaceuticals4.0869 of 5 stars3.31.00.04.14.12.50.6TSVT2seventy bio0.9274 of 5 stars0.94.00.00.00.62.51.3UNCYUnicycive Therapeutics3.4175 of 5 stars3.85.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePVLAPalvella Therapeutics 3.13Buy$46.2990.48% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63400.80% UpsideTSVT2seventy bio 1.80Reduce$4.25-15.00% DownsideUNCYUnicycive Therapeutics 3.50Strong Buy$6.00920.41% UpsideCurrent Analyst Ratings BreakdownLatest UNCY, TSVT, TERN, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$9.005/16/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $52.005/13/2025TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.005/10/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)4/30/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/24/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)4/21/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.004/21/2025UNCYUnicycive TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/11/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/9/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.004/8/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPVLAPalvella Therapeutics$42.81M6.28N/AN/A$21.66 per share1.12TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ATSVT2seventy bio$48.37M5.50N/AN/A$5.04 per share0.99UNCYUnicycive Therapeutics$680K104.31N/AN/A($0.11) per share-5.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePVLAPalvella Therapeutics-$24.54M-$12.10N/AN/AN/AN/A-80.93%-59.55%8/13/2025 (Estimated)TERNTerns Pharmaceuticals-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%8/4/2025 (Estimated)TSVT2seventy bio-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)UNCYUnicycive Therapeutics-$30.54M-$0.51N/AN/AN/AN/AN/A-29.88%N/ALatest UNCY, TSVT, TERN, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/14/2025Q1 2025UNCYUnicycive Therapeutics-$0.14-$0.05+$0.09-$0.05N/AN/A5/8/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/A5/7/2025Q1 2025TSVT2seventy bio-$0.10$0.01+$0.11$0.01$13.96 million$22.94 million3/27/2025Q4 2024UNCYUnicycive Therapeutics-$0.13-$0.26-$0.13-$0.26N/AN/A3/25/2025Q4 2024TSVT2seventy bio-$0.23-$0.31-$0.08-$0.37$12.84 million$2.93 million3/20/2025Q4 2024TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPVLAPalvella TherapeuticsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ATSVT2seventy bioN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPVLAPalvella TherapeuticsN/A4.824.82TERNTerns PharmaceuticalsN/A32.9932.99TSVT2seventy bioN/A4.954.95UNCYUnicycive TherapeuticsN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPVLAPalvella Therapeutics40.11%TERNTerns Pharmaceuticals98.26%TSVT2seventy bio93.90%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipPVLAPalvella Therapeutics20.50%TERNTerns Pharmaceuticals1.50%TSVT2seventy bio7.20%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePVLAPalvella TherapeuticsN/A11.06 million10.50 millionN/ATERNTerns Pharmaceuticals4087.34 million72.11 millionNot OptionableTSVT2seventy bio44053.23 million47.87 millionOptionableUNCYUnicycive Therapeutics9120.63 million78.78 millionNot OptionableUNCY, TSVT, TERN, and PVLA HeadlinesRecent News About These CompaniesQ2 Earnings Estimate for UNCY Issued By HC WainwrightMay 31 at 1:31 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for UNCY Q2 Earnings?May 30 at 7:51 AM | marketbeat.comQ4 Earnings Estimate for UNCY Issued By HC WainwrightMay 29 at 7:42 AM | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Raised to Strong-Buy at HC WainwrightMay 29 at 1:15 AM | americanbankingnews.comUnicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC WainwrightMay 28 at 8:15 AM | marketbeat.comUnicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor ConferencesMay 22, 2025 | quiverquant.comUnicycive Therapeutics to Present at Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comUnicycive Therapeutics Announces Time Change for 2025 Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comQ2 Earnings Forecast for UNCY Issued By Noble FinancialMay 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Acquired by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deUnicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | globenewswire.comAlyeska Investment Group L.P. Trims Stock Holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)May 9, 2025 | marketbeat.comAnalysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before LongMay 7, 2025 | finance.yahoo.comUnicycive Therapeutics (UNCY) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 39.2% in AprilMay 1, 2025 | marketbeat.comNantahala Capital Management LLC Increases Holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)April 30, 2025 | marketbeat.comGuggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy RecommendationApril 22, 2025 | msn.comUnicycive Therapeutics initiated with a Buy at GuggenheimApril 22, 2025 | markets.businessinsider.comUnicycive presents new patient-level data from Phase 2 study of OLCApril 12, 2025 | markets.businessinsider.comUnicycive Therapeutics price target raised to $7.50 from $4 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBuybacks and Big-Time Developments: 3 Stocks Making Huge MovesBy Leo Miller | May 19, 2025View Buybacks and Big-Time Developments: 3 Stocks Making Huge MovesBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International Markets3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%UNCY, TSVT, TERN, and PVLA Company DescriptionsPalvella Therapeutics NASDAQ:PVLA$24.30 -0.48 (-1.94%) As of 05/30/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Terns Pharmaceuticals NASDAQ:TERN$3.12 +0.02 (+0.65%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.14 +0.02 (+0.77%) As of 05/30/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.2seventy bio NASDAQ:TSVT$5.00 0.00 (0.00%) As of 05/13/20252seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Unicycive Therapeutics NASDAQ:UNCY$0.59 0.00 (-0.34%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.58 0.00 (-0.51%) As of 05/30/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
